LIQUIDMETAL TECHNOLOGIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LIQUIDMETAL TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $77.0K | Mar 14, 2023 |
| FY2022 | Sep 30, 2022 | $18.0K | Mar 14, 2023 |
| FY2022 | Jun 30, 2022 | $125.0K | Mar 14, 2023 |
| FY2022 | Mar 31, 2022 | $163.0K | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $90.0K | Mar 14, 2023 |
| FY2022 | Sep 30, 2021 | $406.0K | Mar 14, 2023 |
| FY2022 | Jun 30, 2021 | $243.0K | Mar 14, 2023 |
| FY2022 | Mar 31, 2021 | $72.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $558.0K | Mar 29, 2022 |
| FY2021 | Sep 30, 2020 | $327.0K | Mar 29, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $1.01M | Oct 7, 2014 |
| FY2013 | Dec 31, 2012 | $591.0K | Oct 7, 2014 |
| FY2012 | Dec 31, 2011 | $572.0K | Feb 26, 2013 |
| FY2011 | Dec 31, 2010 | $567.0K | Mar 30, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $230.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $217.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $149.0K | Mar 13, 2025 |
| FY2022 | Dec 31, 2022 | $4.0K | Mar 14, 2023 |
| FY2022 | Sep 30, 2022 | $3.0K | Mar 14, 2023 |
| FY2022 | Jun 30, 2022 | $41.0K | Mar 14, 2023 |
| FY2022 | Mar 31, 2022 | $19.0K | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | ($10.0K) | Mar 14, 2023 |
| FY2022 | Sep 30, 2021 | $87.0K | Mar 14, 2023 |
| FY2022 | Jun 30, 2021 | $89.0K | Mar 14, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.34M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($1.51M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($2.05M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($2.39M) | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | ($3.38M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($2.64M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($7.43M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($8.70M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($8.69M) | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | ($18.74M) | Mar 5, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.74M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($3.31M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($3.09M) | Mar 13, 2025 |
| FY2022 | Dec 31, 2022 | ($750.0K) | Mar 14, 2023 |
| FY2022 | Sep 30, 2022 | ($760.0K) | Mar 14, 2023 |
| FY2022 | Jun 30, 2022 | ($747.0K) | Mar 14, 2023 |
| FY2022 | Mar 31, 2022 | ($795.0K) | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | ($809.0K) | Mar 14, 2023 |
| FY2022 | Sep 30, 2021 | ($1.57M) | Mar 14, 2023 |
| FY2022 | Jun 30, 2021 | ($798.0K) | Mar 14, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $19.0K | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $20.0K | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $55.0K | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | $84.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $110.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $1.34M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $2.43M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $1.96M | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | $2.34M | Mar 5, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.96M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $3.51M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $3.21M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.06M | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.16M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.80M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.42M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $5.90M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $6.27M | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | $7.47M | Mar 5, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.75M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($1.16M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($1.31M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($1.78M) | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | ($2.73M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($2.23M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($3.87M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($6.25M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($7.66M) | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | ($7.82M) | Mar 5, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.0K | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 12, 2026 |
| FY2021 | Dec 31, 2021 | $0 | Mar 29, 2022 |
| FY2021 | Dec 31, 2020 | $116.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $630.0K | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $292.0K | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $11.87M | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | $198.0K | Mar 5, 2019 |
| FY2017 | Dec 31, 2015 | $675.0K | Mar 6, 2018 |
| FY2016 | Dec 31, 2014 | $1.06M | Mar 10, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.11M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $30.40M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $31.84M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $33.34M | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | $35.61M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $38.81M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $41.33M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $47.85M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $55.08M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $61.37M | Mar 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.03M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $1.26M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $1.25M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.30M | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | $1.31M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.42M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $1.76M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.41M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $3.51M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $6.54M | Mar 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | ($2.23M) | Mar 30, 2012 |
| FY2011 | Dec 31, 2010 | ($10.65M) | Mar 30, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($280.59M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($278.25M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($276.74M) | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | ($274.70M) | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | ($272.30M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($268.93M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($266.28M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($258.85M) | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | ($245.38M) | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | ($236.69M) | Mar 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.16M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $6.01M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $8.84M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | $2.27M | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | $4.09M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.51M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $19.54M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $35.23M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | $41.31M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | $58.90M | Mar 6, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 13, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 14, 2023 |
| FY2022 | Sep 30, 2022 | 0 | Mar 14, 2023 |
| FY2022 | Jun 30, 2022 | 0 | Mar 14, 2023 |
| FY2022 | Mar 31, 2022 | 0 | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
| FY2022 | Sep 30, 2021 | 0 | Mar 14, 2023 |
| FY2022 | Jun 30, 2021 | 0 | Mar 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Nov 21, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 5, 2019 |
| FY2018 | Dec 31, 2016 | 0 | Mar 5, 2019 |
| FY2017 | Dec 31, 2015 | 0 | Mar 6, 2018 |
| FY2016 | Dec 31, 2014 | 0 | Mar 10, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 917.29M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 917.29M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 917.29M | Mar 13, 2025 |
| FY2023 | Dec 31, 2022 | 917.29M | Nov 21, 2024 |
| FY2022 | Dec 31, 2021 | 914.45M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 914.45M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | 914.45M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 914.21M | Mar 10, 2020 |
| FY2018 | Dec 31, 2017 | 908.77M | Mar 5, 2019 |
| FY2017 | Dec 31, 2016 | 886.09M | Mar 6, 2018 |